124027-47-0

Basic information

• Product Name: 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL
• Synonyms: 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL;1-Hydroxytacrine;PD-131620
• CAS NO: 124027-47-0
• Molecular Formula: C13H14N2O
• Molecular Weight: 214.26
• Product Categories: pharmacetical
• Mol File: 124027-47-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 245℃
• Boiling Point: 450.3°Cat760mmHg
• Flash Point: 226.1°C
• Appearance: /
• Density: 1.315g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL(124027-47-0)
• EPA Substance Registry System: 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL(124027-47-0)

Safety Data

• Hazardous Substances Data: 124027-47-0(Hazardous Substances Data)

Usage

General Description

9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL is a chemical compound with the molecular formula C13H14N2O. It is an amino derivative of acridine and contains a tetrahydroacridinol backbone. 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL has potential pharmaceutical applications and is being studied for its medicinal properties, particularly for its potential use as an anti-tumor and anti-inflammatory agent. It is also being investigated for its potential neuroprotective and anti-Alzheimer's disease properties. Additionally, 9-AMINO-1,2,3,4-TETRAHYDRO-ACRIDIN-1-OL has been studied for its ability to inhibit acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine, which is important for memory and cognitive function.

Upstream product

• 104675-26-5 9-Amino-1,2,3,4-tetrahydroacridin-1-one 
• 1684-40-8 tacrine monohydrochloride 
• 504-02-9 1,3-cylohexanedione 
• 104675-23-2 N-(3-oxocyclohexen-1-yl)-2-aminobenzonitrile 
• 1885-29-6 anthranilic acid nitrile 
• 67-63-0 isopropyl alcohol 

Relevant articles and documents

Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: In vitro/in vivo comparisons

1. Incubations of tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate, THA) with a primary suspension of rat hepatocytes for 2 min resulted in formation of the 1-hydroxy derivative as the major metabolite with smaller amounts of the 2- and 4-hydroxy metabolites. 2. Apparent V(max) and K(m) for THA metabolism were 12.4 ± 3.3 nmol/min/g liver and 0.98 ± 0.34 μM respectively. 3. Incubations of THA for longer time-periods (> 10 min) resulted in irreversible binding of THA-derived radioactivity to hepatocellular protein. The apparent maximal rate of irreversible binding (B(max)) was 76.7 ± 30.5 pmol equivalents bound/h/mg cell protein, whereas the apparent K(b) for binding was 2.8 ± 1.4 μM. 4. The kinetic parameters, V(max) and K(m), were used to predict steady-state extraction ratios (ER(SS)) for various THA input concentrations (C(in)) in single-pass perfused rat liver. At low input concentrations (0.72-0.85 μM; C(in) K(m)), ER(SS) of THA was approximately 1. For higher C(in) (14.05, 20.72, 20.88 μM; C(in) ≥ K(m)), the calculated ER(SS) was markedly decreased with 0.300, 0.296 and 0.261, respectively. 5. The intrinsic clearance of THA (Cl(i)) estimated from in vitro hepatocyte data was 6.7 ml/min/g liver while the apparent oral THA clearance (Cl(oral)) calculated from in vivo rat data was 6.6 ml/min/g liver.

Use of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds for the treatment of aids

There is disclosed the use of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds of the formula below, where Xis hydrogen, loweralkyl or halogen; and Ris hydrogen, loweralkyl or benzyl; for the treatment of acquired immune deficiency syndrome (AIDS).

9-Amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments

-